Maternal respiratory syncytial virus (RSV) vaccination and nirsevimab were associated with a reduction in RSV-associated ...

Interim surveillance network data showed lower hospitalization rates following the availability of prevention products.

Maternal RSV vaccination and nirsevimab were associated with a reduction in RSV hospitalization rates in infants aged 0 to 7 months during the 2024-2025 RSV season.

New findings provide compelling evidence for the protective benefits of maternal RSVpreF vaccination during pregnancy.

New respiratory syncytial virus (RSV) prevention products significantly reduce infant hospitalization rates, highlighting the ...

Recent data shows that most infants are receiving RSV vaccination in the US, but rates vary by race and birth month.

The number of COVID-19 infections in China has been steadily rising since early April, but the overall spread of acute ...

Maternal RSV vaccination and nirsevimab were associated with a reduction in hospitalization rates among infants aged 0 to 7 months.

New multi-center US study finds RSV co-infection in children under two is not linked to worse clinical outcomes, challenging ...

A comprehensive new study reveals that respiratory syncytial virus (RSV) vaccines provide strong protection for adults aged ...

The infant mortality national rate dropped to about 5.5 infant deaths per 1,000 live births in 2024, according to provisional ...

The U.S. Centers for Disease Control and Prevention in a report on Thursday said that hospitalizations related to RSV ...